BGLC - Company ID 0001737523
The table below shows BioNexus Gene Lab Corp's cash flow statement by quarter, as reported in the company's quarterly filings. All figures are in US dollars; negative values appear in red.
| Line item | Q1 2026 | Q1 2025 | Q1 2024 | Q1 2023 | Q1 2022 | Q1 2021 |
|---|---|---|---|---|---|---|
| Operating cash flow | -$147.67K | -$824.07K | -$37.15K | -$116.52K | -$37.84K | $115.43K |
| Capital expenditure | $325.00 | $9.05K | $21.95K | $102.00 | $32.19K | $807.00 |
| Investing cash flow | -$13.99K | -$15.65K | $3.65K | -$5.06K | -$197.13K | -$295.83K |
| Dividends paid | - | - | - |
BioNexus Gene Lab Corp reported operating cash flow of -$1.84M for fiscal year 2025. That is up 12.2% from -$2.09M in fiscal 2024. Over the 8 fiscal years shown, operating cash flow declined from -$274.08K (FY 2018) to -$1.84M. Figures come from the company's audited annual reports as filed with the SEC.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| - |
| - |
| - |
| Stock buybacks | - | - | - | - | - | - |
| Financing cash flow | $59.71K | -$860.00 | $26.93K | -$1.78K | $0.00 | -$8.55K |